These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 24126578)

  • 41. Novel Antimycobacterial Compounds Suppress NAD Biogenesis by Targeting a Unique Pocket of NaMN Adenylyltransferase.
    Osterman AL; Rodionova I; Li X; Sergienko E; Ma CT; Catanzaro A; Pettigrove ME; Reed RW; Gupta R; Rohde KH; Korotkov KV; Sorci L
    ACS Chem Biol; 2019 May; 14(5):949-958. PubMed ID: 30969758
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antimycobacterial activity of novel 1-(5-cyclobutyl-1,3-oxazol-2-yl)-3-(sub)phenyl/pyridylthiourea compounds endowed with high activity toward multidrug-resistant Mycobacterium tuberculosis.
    Sriram D; Yogeeswari P; Dinakaran M; Thirumurugan R
    J Antimicrob Chemother; 2007 Jun; 59(6):1194-6. PubMed ID: 17449482
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Detection of inhibitors of phenotypically drug-tolerant Mycobacterium tuberculosis using an in vitro bactericidal screen.
    Bassett IM; Lun S; Bishai WR; Guo H; Kirman JR; Altaf M; O'Toole RF
    J Microbiol; 2013 Oct; 51(5):651-8. PubMed ID: 23800952
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles.
    Sasaki H; Haraguchi Y; Itotani M; Kuroda H; Hashizume H; Tomishige T; Kawasaki M; Matsumoto M; Komatsu M; Tsubouchi H
    J Med Chem; 2006 Dec; 49(26):7854-60. PubMed ID: 17181168
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mechanisms of resistance against NITD-916, a direct inhibitor of Mycobacterium tuberculosis InhA.
    McNeil MB; Dennison D; Shelton C; Flint L; Korkegian A; Parish T
    Tuberculosis (Edinb); 2017 Dec; 107():133-136. PubMed ID: 29050761
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Advanced Quantification Methods To Improve the 18b Dormancy Model for Assessing the Activity of Tuberculosis Drugs
    Pieterman ED; Sarink MJ; Sala C; Cole ST; de Steenwinkel JEM; Bax HI
    Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32340993
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit Mycobacterium tuberculosis dihydrofolate reductase.
    Gerum AB; Ulmer JE; Jacobus DP; Jensen NP; Sherman DR; Sibley CH
    Antimicrob Agents Chemother; 2002 Nov; 46(11):3362-9. PubMed ID: 12384337
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ion Channel Blockers as Antimicrobial Agents, Efflux Inhibitors, and Enhancers of Macrophage Killing Activity against Drug Resistant Mycobacterium tuberculosis.
    Machado D; Pires D; Perdigão J; Couto I; Portugal I; Martins M; Amaral L; Anes E; Viveiros M
    PLoS One; 2016; 11(2):e0149326. PubMed ID: 26919135
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Synthesis and in vitro antitubercular activity of pyridine analouges against the resistant Mycobacterium tuberculosis.
    Patel H; Chaudhari K; Jain P; Surana S
    Bioorg Chem; 2020 Sep; 102():104099. PubMed ID: 32711084
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Simple model for testing drugs against nonreplicating Mycobacterium tuberculosis.
    Sala C; Dhar N; Hartkoorn RC; Zhang M; Ha YH; Schneider P; Cole ST
    Antimicrob Agents Chemother; 2010 Oct; 54(10):4150-8. PubMed ID: 20679505
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Novel inhibitors of InhA efficiently kill Mycobacterium tuberculosis under aerobic and anaerobic conditions.
    Vilchèze C; Baughn AD; Tufariello J; Leung LW; Kuo M; Basler CF; Alland D; Sacchettini JC; Freundlich JS; Jacobs WR
    Antimicrob Agents Chemother; 2011 Aug; 55(8):3889-98. PubMed ID: 21628538
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Occurrence of disputed rpoB mutations among Mycobacterium tuberculosis isolates phenotypically susceptible to rifampicin in a country with a low incidence of multidrug-resistant tuberculosis.
    Al-Mutairi NM; Ahmad S; Mokaddas E; Eldeen HS; Joseph S
    BMC Infect Dis; 2019 Jan; 19(1):3. PubMed ID: 30606116
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vitro bactericidal activity of oxazolidinone, RBx 8700 against Mycobacterium tuberculosis and Mycobacterium avium complex.
    Rao M; Sood R; Malhotra S; Fatma T; Upadhyay DJ; Rattan A
    J Chemother; 2006 Apr; 18(2):144-50. PubMed ID: 16736882
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vitro anti-tuberculosis activity of azole drugs against Mycobacterium tuberculosis clinical isolates.
    Imperiale BR; Cataldi ÁA; Morcillo NS
    Rev Argent Microbiol; 2017; 49(4):332-338. PubMed ID: 28919150
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fighting tuberculosis by drugs targeting nonreplicating
    Iacobino A; Piccaro G; Giannoni F; Mustazzolu A; Fattorini L
    Int J Mycobacteriol; 2017; 6(3):213-221. PubMed ID: 28776518
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antibacterial Activity of combinatorial treatments composed of transition-metal/antibiotics against Mycobacterium tuberculosis.
    Montelongo-Peralta LZ; León-Buitimea A; Palma-Nicolás JP; Gonzalez-Christen J; Morones-Ramírez JR
    Sci Rep; 2019 Apr; 9(1):5471. PubMed ID: 30940878
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 5-Nitrofuran-2-yl derivatives: synthesis and inhibitory activities against growing and dormant mycobacterium species.
    Sriram D; Yogeeswari P; Dhakla P; Senthilkumar P; Banerjee D; Manjashetty TH
    Bioorg Med Chem Lett; 2009 Feb; 19(4):1152-4. PubMed ID: 19131245
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Phenotypic Based Target Screening Approach Delivers New Antitubercular CTP Synthetase Inhibitors.
    Esposito M; Szadocka S; Degiacomi G; Orena BS; Mori G; Piano V; Boldrin F; Zemanová J; Huszár S; Barros D; Ekins S; Lelièvre J; Manganelli R; Mattevi A; Pasca MR; Riccardi G; Ballell L; Mikušová K; Chiarelli LR
    ACS Infect Dis; 2017 Jun; 3(6):428-437. PubMed ID: 28475832
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combination of anti-tuberculosis drugs with vitamin C or NAC against different Staphylococcus aureus and Mycobacterium tuberculosis strains.
    Khameneh B; Fazly Bazzaz BS; Amani A; Rostami J; Vahdati-Mashhadian N
    Microb Pathog; 2016 Apr; 93():83-7. PubMed ID: 26602814
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Biological evaluation of novel substituted chloroquinolines targeting mycobacterial ATP synthase.
    Khan SR; Singh S; Roy KK; Akhtar MS; Saxena AK; Krishnan MY
    Int J Antimicrob Agents; 2013 Jan; 41(1):41-6. PubMed ID: 23141113
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.